Angelman Syndrome Foundation

Applications are invited for AS-related research projects. Priority will be given to projects focused on studying or correcting the heterozygous effect of non-UBE3A genes in deletion; the potential results of increasing UBE3A after therapies or for some subtypes of AS; the delivery of therapies and potential for improvement; and symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.